{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:56:19Z","timestamp":1763765779012,"version":"3.37.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.neuropharm.2009.03.003","type":"journal-article","created":{"date-parts":[[2009,3,18]],"date-time":"2009-03-18T08:43:02Z","timestamp":1237365782000},"page":"1075-1081","source":"Crossref","is-referenced-by-count":14,"title":["MPTP-induced model of Parkinson's disease in cytochrome P450 2E1knockout mice"],"prefix":"10.1016","volume":"56","author":[{"given":"C.","family":"Viaggi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Vaglini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Caramelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.U.","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2009.03.003_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0006-8993(93)91721-4","article-title":"Induction of brain cytochrome P-450IIE1 by chronic ethanol treatment","volume":"601","author":"Anandatheerthavarada","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1006\/bbrc.1993.1821","article-title":"Differential effect of chronic nicotine administration on brain cytochrome P4501A1\/2 and P4502E1","volume":"194","author":"Anandatheerthavarada","year":"1993","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0140-6736(97)03495-8","article-title":"Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease","volume":"350","author":"Bandmann","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(85)90743-3","article-title":"Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine","volume":"2","author":"Barbeau","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1471-4159.1985.tb04045.x","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro","volume":"45","author":"Bocchetta","year":"1985","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib6","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0022-3565(24)38317-X","article-title":"Catalytic activity and quantitation of cytochrome P-450 2E1 in prenatal human brain","volume":"289","author":"Brzezinski","year":"1999","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0006-291X(84)91293-2","article-title":"Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase","volume":"120","author":"Chiba","year":"1984","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib8","series-title":"Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-662-06765-9_11","article-title":"Molecular and cellular events regulating dopamine neuron survival","volume":"Vol. 154","author":"Corsini","year":"2002"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib9","first-page":"147","article-title":"Current protocols for light microscopy immunocytochemistry","author":"Cot\u00e8","year":"1993"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib10","first-page":"248","article-title":"Association of CYP2E1 gene polymorphism with predisposition to cancer development","volume":"27","author":"Danko","year":"2005","journal-title":"Exp. Oncol"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-1781(79)90006-4","article-title":"Chronic Parkinsonism secondary to intravenous injection of meperidine analogues","volume":"1","author":"Davis","year":"1979","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3565(25)12474-9","article-title":"Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues","volume":"253","author":"de Waziers","year":"1990","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib13","first-page":"293","article-title":"High-affinity binding of [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location. Eur","volume":"202","author":"Del Zompo","year":"1991","journal-title":"J. Pharmacol"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02260902","article-title":"Localization of MPP+ binding sites in the brain of various mammalian species","volume":"4","author":"Del Zompo","year":"1992","journal-title":"J. Neural. Transm. Park. Dis. Dement. Sect"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib15","first-page":"411","article-title":"Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br","volume":"109","author":"Del Zompo","year":"1993","journal-title":"J. Pharmacol"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1471-4159.1987.tb02909.x","article-title":"A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"49","author":"Denton","year":"1987","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0006-291X(86)91211-8","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes","volume":"137","author":"Di Monte","year":"1986","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/15287399309531797","article-title":"Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue","volume":"40","author":"Farin","year":"1993","journal-title":"J. Toxicol. Environ. Health"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1471-4159.1966.tb09873.x","article-title":"Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain","volume":"13","author":"Glowinski","year":"1966","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.106.012492","article-title":"The 2006 Bernard B. Brodie Award Lecture. Cyp2E1. Drug Metab","volume":"35","author":"Gonzalez","year":"2007","journal-title":"Dispos"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/0049825031000086400","article-title":"Functional characterization of three human cytochrome p450 2E1 variants with amino acid substitutions","volume":"33","author":"Hanioka","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0306-4522(90)90154-V","article-title":"Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system","volume":"34","author":"Hansson","year":"1990","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0026-895X(24)13476-1","article-title":"Genetic polymorphism of human CYP2E1: characterization of two variant alleles","volume":"51","author":"Hu","year":"1997","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00210-003-0819-z","article-title":"Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms","volume":"369","author":"Ingelman-Sundberg","year":"2004","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib25","first-page":"455","article-title":"Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur","volume":"106","author":"Javitch","year":"1984","journal-title":"J. Pharmacol"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib26","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.82.7.2173","article-title":"Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity","volume":"82","author":"Javitch","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-3565(25)29664-1","article-title":"Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo","volume":"187","author":"Jollow","year":"1973","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib28","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1523\/JNEUROSCI.18-06-01979.1998","article-title":"Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter","volume":"18","author":"Jones","year":"1998","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.neuropharm.2005.11.001","article-title":"Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine","volume":"50","author":"Joshi","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0891-5849(94)90245-3","article-title":"The oxidative inactivation of cytochrome P450 in monooxygenase reactions","volume":"16","author":"Karuzina","year":"1994","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib31","series-title":"Handbook of Experimental Pharmacology","first-page":"333","article-title":"Mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced destruction of dopaminergic neurons","volume":"Vol. 102","author":"Kopin","year":"1992"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib32","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib33","doi-asserted-by":"crossref","first-page":"12063","DOI":"10.1074\/jbc.271.20.12063","article-title":"Role of CYP2E1 in the hepatotoxicity of acetaminophen","volume":"271","author":"Lee","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.burns.2003.09.004","article-title":"Nerve quantification in female red Duroc pig (FRDP) scar compared to human hypertrophic scar","volume":"30","author":"Liang","year":"2004","journal-title":"Burns"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1152\/physrev.1997.77.2.517","article-title":"Cytochrome P-4502E1: its physiological and pathological role","volume":"77","author":"Lieber","year":"1997","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/jhep.2001.22521","article-title":"Induction of catalase, alpha, and microsomal glutathione S-transferase in CYP2E1 overexpressing HepG2 cells and protection against short-term oxidative stress","volume":"33","author":"Mar\u00ed","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/311464a0","article-title":"Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism","volume":"311","author":"Markey","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1006\/taap.1998.8532","article-title":"A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake","volume":"152","author":"McCarver","year":"1998","journal-title":"Toxicol. Appl. Pharmacol"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(25)29666-5","article-title":"Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione","volume":"187","author":"Mitchell","year":"1973","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1749-6632.2002.tb04083.x","article-title":"Nitric oxide: an antioxidant and neuroprotector. Ann. N.Y","volume":"962","author":"Mohanakumar","year":"2002","journal-title":"Acad. Sci"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib41","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1046\/j.1471-4159.1995.65062561.x","article-title":"Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes","volume":"65","author":"Montoliu","year":"1995","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0306-4522(03)00330-0","article-title":"An investigation of dopaminergic metabolites in the striatum and in the substantia nigra in vivo utilising radiolabelled l-DOPA and high performance liquid chromatography: a new approach in the search for transmitter metabolites","volume":"120","author":"Niazi Shahabi","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/syn.20505","article-title":"Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production","volume":"62","author":"Niazi Shahabi","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib44","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/0024-3205(85)90146-8","article-title":"Inhibition of NADH linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"36","author":"Nicklas","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/syn.1052","article-title":"Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway?","volume":"40","author":"Nissbrandt","year":"2001","journal-title":"Synapse"},{"year":"2001","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.neuropharm.2009.03.003_bib46"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib47","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1016\/S0021-9258(19)57434-8","article-title":"Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria","volume":"261","author":"Ramsay","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0006-8993(96)00746-9","article-title":"Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera","volume":"743","author":"Riedl","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib49","series-title":"Cytochromes P450: Metabolic and Toxicological Aspects","article-title":"The CYP2 Subfamily","author":"Ronis","year":"1996"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/alcalc\/28.Supplement_1B.69","article-title":"Immunohistochemical demonstration of ethanol-inducible P450 2E1 in rat brain","volume":"1B","author":"Sohda","year":"1993","journal-title":"Alcohol Alcohol Suppl."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib51","series-title":"Handbook of Parkinson's Disease","first-page":"319","article-title":"MPTP and animal models of Parkinson's disease","author":"Sonsalla","year":"1992"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0022-3565(24)39240-7","article-title":"Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata","volume":"293","author":"Staal","year":"2000","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib53","first-page":"99","article-title":"The role of NADH in uncoupled microsomal monoxygenations. Eur","volume":"46","author":"Staudt","year":"1974","journal-title":"J. Biochem"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib54","doi-asserted-by":"crossref","first-page":"9730","DOI":"10.1073\/pnas.89.20.9730","article-title":"Homology of a vesicular amine transporter to a gene conferring resistance to 1-methyl-4-phenylpyridinium","volume":"89","author":"Stern-Bach","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.10332","article-title":"Pathogenic role of glial cells in Parkinson's disease","volume":"18","author":"Teismann","year":"2003","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib56","first-page":"2563","article-title":"Polyclonal and monoclonal antibodies as probes of rat hepatic cytochrome P-450 isozymes","volume":"46","author":"Thomas","year":"1987","journal-title":"Fed. Proc."},{"key":"10.1016\/j.neuropharm.2009.03.003_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0003-9861(92)90358-4","article-title":"Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme","volume":"293","author":"Tierney","year":"1992","journal-title":"Arch. Biochem. Biophys"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1006\/abbi.1999.1477","article-title":"Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization","volume":"373","author":"Upadhya","year":"2000","journal-title":"Arch. Biochem. Biophys"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1471-4159.2004.02720.x","article-title":"Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease","volume":"91","author":"Vaglini","year":"2004","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib60","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/1531-8257(200011)15:6<1267::AID-MDS1035>3.0.CO;2-W","article-title":"Lack of association between cytochrome P450 2E1 gene polymorphisms and Parkinson's disease in a Chinese population","volume":"15","author":"Wang","year":"2000","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0306-4522(97)00649-0","article-title":"Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase","volume":"86","author":"Watts","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2009.03.003_bib62","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-002-0721-8","article-title":"Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese","volume":"109","author":"Wu","year":"2002","journal-title":"J. Neural Transm"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390809000707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390809000707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T13:56:05Z","timestamp":1739022965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390809000707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0028390809000707"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2009.03.003","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}